Rezolute Completes Enrollment In Open-Label Phase 3 Study Of Ersodetug In Tumor HI; Topline Data Expected In Mid-December 2026

Rezolute, Inc. (NASDAQ:RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that the open-label